GoodRx is a buy that can surge 60% from here, Citi says

By December 2, 2022Health

The sell-off in telemedicine name GoodRx is overdone, and now is a good time to buy the stock, according to Citi.

Spread the love
See also  Medical device stocks tend to beat the market, and analysts expect these names to see big gains

Leave a Reply